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Currently, there is a growing interest in combining anticancer drugs with 
the aim to improve outcome in patients suffering from tumours and reduce the 
long-term toxicity associated with the current standard of treatment. In this study, 
we evaluated the possible role of deracoxib against the toxicity of doxorubicin on 
normal canine mammary epithelial cells. The effect of deracoxib and doxorubicin 
combination on cell viability was determined by MTT assay. Apoptosis was char-
acterised by flow cytometry. Cell nitrite concentrations were measured with the 
Griess reaction. Deracoxib (50 and 100 μM) treatment decreased the cytotoxic ac-
tion of doxorubicin at 0.9 μM in the cells, from 33.63% to 13.4% and 25.82%, re-
spectively. Our results also showed that the reverse effect of deracoxib on 
doxorubicin-induced cytotoxic activity in the cells was associated with a marked 
(3.04- to 3.57-fold) decrease in apoptosis. In additional studies identifying the 
mechanism of the observed effect, deracoxib exhibited an activity to prevent 
doxorubicin-mediated overproduction of nitric oxide in the cells. Our in vitro 
study results indicate that deracoxib (50 and 100 μM) can be beneficial in protect-
ing normal cells from the toxic effect of doxorubicin in conjunction with apop-
tosis by the modulation of nitric oxide production.  
Key words: Deracoxib, doxorubicin, cell viability, apoptosis, nitric oxide  
Mammary tumours rank as the second most common neoplasms in dogs 
after skin tumours (Rai et al., 2014). The occurrence of malignant forms is re-
ported to vary from 26 to 73%, carcinoma being the most common malignant 
type (Karayannopoulou et al., 2005). However, most reports on canine mammary 
tumours focus on the histopathogenic aspects of the lesions, while the mecha-
nisms of progression and the biological behaviour of the disease are not well un-
derstood. Therefore, information concerning the prognosis and treatment options 
                                                 
*Corresponding author; E-mail: fustun@istanbul.edu.tr; Phone: 0090 (212) 473-7070; 
Fax: 0090 (212) 473-7241 
 EFFECTS OF DOXORUBICIN AND DERACOXIB ON CANINE MAMMARY CELLS 367 
Acta Veterinaria Hungarica 65, 2017 
of canine mammary tumours is scarce and very limited (Pereira et al., 2009). 
Currently, there is no curative therapy especially for metastatic mammary tu-
mours. Surgical excision still remains the treatment of choice for canine mam-
mary tumours, although it alone yields unsatisfactory results in dogs with malig-
nant mammary tumours exhibiting lymphatic or vascular invasion (Simon et al., 
2006). Chemotherapy is recognised as one of the few treatment options that can 
be effective in controlling the distant spread of the disease, so it may help to in-
crease the disease-free interval or the survival time (Karayannopoulou et al., 2001). 
Among the many types of chemotherapeutic drugs, doxorubicin (DOX), either 
alone or in combination with other agents, is a commonly used anticancer drug 
for the treatment of these tumours in veterinary oncology. It is known that the 
lack of success of chemotherapy with DOX as a result of resistance development 
and dose-limiting toxicity is a major issue in the clinical management of the neo-
plasms (Pagnini et al., 2000; Todorova et al., 2005). For this reason, alternative 
remedies are needed to increase the therapeutic efficacy and minimise the sys-
temic toxicity of the chemotherapeutic agent against mammary tumours in dogs. 
In recent years, extensive research has been focused on the use of nonsteroidal 
anti-inflammatory drugs (NSAIDs), which have anti-tumourigenic and chemo-
therapeutic effects in several different types of cancer, in combination with anti-
cancer drugs as a novel treatment option (Wolfesberger et al., 2006; van 
Wijngaarden et al., 2007; Falandry et al., 2009).  
COX-2 is overexpressed along the continuum of oncogenesis and is likely 
to be a key player in a number of biologic pathways leading to cancer. Current 
evidence indicates that COX-2 promotes tumour-specific angiogenesis, inhibits 
apoptosis, and induces proangiogenic factors such as VEGF and inducible nitro-
gen oxide synthase promoter (iNOS) (Koki and Masferrer, 2002). Recent studies 
have reported that COX-2 was overexpressed in canine mammary tumours com-
pared with normal mammary tissue. Since COX-2 expression and staining inten-
sity correlate with the clinical and histologic features of mammary tumour ma-
lignancy, it has been hypothesised that COX-2 inhibitors may be useful in the 
treatment of mammary tumours in dogs (Souza et al., 2009). This hypothesis is 
supported by the results of various experimental and clinical studies indicating 
that NSAIDs, particularly the selective COX-2 inhibitors, have chemotherapeutic 
potential in mammary tumours (Alshafie et al., 2000; Rao and Knaus, 2008; Ustun 
Alkan et al., 2012). Although the significance of these inhibitors is well estab-
lished, the mechanisms underlying their chemopreventive and chemotherapeutic 
actions are largely unknown. Indeed, there is evidence suggesting that these ac-
tions of COX-2 inhibitors have been attributed to both COX-dependent and 
COX-independent mechanisms relating to the induction of cell apoptosis and the 
inhibition of angiogenesis and cell invasion/migration (Alshafie et al., 2000; 
Awara et al., 2004; Patel et al., 2005; Rao and Knaus, 2008). Additional studies 
have indicated that these inhibitors may also sensitise cancer cells to the antipro-
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liferative effects of cytotoxic drugs by different molecular mechanisms such as 
inhibition of Pgp expression and induction of DNA hypermethylation (Hilovska 
et al., 2015). Therefore, combining COX-2 inhibitors with chemotherapeutic drugs 
may allow for the use of a lower dose of cytotoxic drugs and may also enhance 
the effectiveness of therapy. 
One such NSAID is the selective COX-2 inhibitor Deracoxib (DER), 
which is widely used in veterinary medicine for the control of pain and inflam-
mation associated with osteoarthritis and orthopaedic surgery in dogs (Roberts et 
al., 2009). Studies conducted by us have shown that DER at high concentrations 
(500–1000 µM) has anticancer activity against the canine mammary cancer cell 
line CMT-U27 (Ustun Alkan et al., 2012, 2014). Also, our chemo-combination 
study has shown that DER at low concentrations (50–250 µM) enhanced the anti-
proliferative effect of DOX in conjunction with the induction of apoptosis and 
changes in the cell cycle of the CMT-U27 cell line (Bakirel et al., 2016). It is 
known that the rationale underlying combination cytotoxic chemotherapy has 
been to co-administer drugs that work by different molecular mechanisms, 
thereby increasing tumour cell killing without significant toxicity to normal cells 
(Al-Lazikani et al., 2012). In this context, there is one published report demon-
strating the synergistic cytotoxic effects of DOX in combination with DER on 
canine mammary carcinoma cells, but possible effects of the combination on 
normal canine cells have not been investigated to date. Therefore, we decided to 
investigate whether the selective COX-2 inhibitor drug DER could be able to re-
store the response of a chemotherapeutic agent (DOX) on normal canine mam-
mary epithelial cells.  
 
Materials and methods 
Cell culture and chemicals 
Canine mammary epithelial cells were isolated from the mammary gland 
of a healthy female dog as described previously with minor modifications (Wolfe 
et al., 1986; Smalley, 2010) during surgical treatment at the Department of Ob-
stetrics and Gynaecology, Faculty of Veterinary Medicine of Istanbul University. 
Briefly, mammary gland tissue was rinsed in antibiotics (100 IU/ml penicillin, 
100 μg/ml streptomycin and 2.5 μg/ml amphotericin B) and then transferred to a 
sterile glass Petri dish and minced with scalpels until the glands were rendered to 
a paste. For dissociation, the mammary tissue was transferred to a tube contain-
ing collagenase (0.35%) and incubated at 37 °C for 2–6 h. After dissociation, the 
cells were centrifuged at 350 × g for 5 min and the supernatant was discarded. 
The pellet was resuspended with Hanks’ Balanced Salt Solution supplemented 
with 5% fetal bovine serum (FBS) and ammonium chloride solution and centri-
fuged at 350 × g for 5 min. As a result, the pellet contained epithelial cell organ-
oids and fibroblasts. After pre-plating to remove fibroblasts, the organoids were 
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resuspended in Epicult medium (Stemcell Tech, Canada) supplemented with epi-
dermal growth factor (EGF) and transferred to a flask. The cultures were incu-
bated at 37 °C in a humidified atmosphere of 5% CO2. Over a period of several 
(5–7) days, the epithelial cells mobilised and spread out from the organoids to 
form a monolayer. When primary cultures reached confluency, they were subcul-
tured by first washing the adherent cells with DMEM-F12 medium supplemented 
with 10% FBS, followed by incubation with 0.25% trypsin-EDTA solution. 
Once the cells had detached from the flask, an equal volume of DMEM-F12 me-
dium was added and the cell suspension was centrifuged at 350 × g for 5 min. 
Collected cells were then reseeded into the flasks and subcultured every 2–3 
days. DER was a generous gift from Novartis Pharmaceuticals Inc. (Basel, Swit-
zerland). All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
except Epicult medium (Stemcell Technologies, Tokyo, Japan). DOX and DER 
were dissolved in DMEM-F12 and sterile dimethyl sulphoxide (DMSO), respec-
tively, and further serial dilutions of both drugs were made with DMEM-F12. 
The final DMSO concentration did not exceed 0.1% (and had no effect on cell 
growth) in any experimental group, and this condition was used as control in 
each experiment (all groups comprised 0.1% DMSO). All of the stock solutions 
were kept at a temperature of –20 °C. 
Cell viability assay 
Cell viability assay was performed to determine the effects of DOX and 
DER on the viability of canine mammary epithelial cells. For this purpose, cells 
were seeded at a density of 2 × 104 cells/100 μl in 96-well flat bottom microtitre 
plates (Jet Biofil, Canada) in triplicate and incubated in a humidified atmosphere 
at 37 °C under 5% CO2 and 95% air to allow cell adhesion. After 24 h incuba-
tion, medium was removed and cells were treated with various concentrations of 
DOX (0.9 μM) and DER (50, 100 and 250 μM) for 72 h. The concentrations for 
DOX and DER were chosen on the basis of our previous reports about the effects 
of these drugs on the in vitro viability of canine mammary tumour cells (Ustun 
Alkan et al., 2014; Bakirel et al., 2016). In addition, the tested concentration of 
DOX (0.9 μM) was within the range of the clinically relevant concentration and 
the chosen concentrations of DER (50–250 μM) cannot lead to toxicity in canine 
mammary tumour cells (Bakirel et al., 2016). Cell viability was assessed using a 
cell proliferation kit (MTT, Roche, Germany) according to the manufacturer’s 
instructions. Briefly, 10 μl of MTT solution [5 mg/ml in phosphate buffered sa-
line (PBS)] was added to each well and incubated for 4 h at 37 °C in a CO2 incu-
bator. The purple water-insoluble formazan salt was then dissolved with 10% 
SDS in 0.01 M HCl and incubated overnight in a humidified 5% CO2 atmos-
phere. The optical densities (OD) of the wells were measured at 550 nm by a mi-
croplate reader (ELx800, Biotek Instruments, USA). The effect of each com-
pound on growth inhibition was assessed as percent cell viability where control 
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cells were taken as 100% viable. Subsequently, we tested 0.9 μM of DOX with 
50, 100 and 250 μM of DER in combination to determine the possible effect of 
DER against DOX toxicity on normal canine mammary epithelial cells. The cells 
were treated with DOX and DER for 72 h and the effects of the combined agents 
on cell viability were evaluated according to the MTT assay as described above. 
Apoptosis assay 
An apoptosis assay was performed to determine the effects of DER and DOX 
on apoptosis in normal canine mammary epithelial cells. Flow cytometric analy-
ses of phosphatidylserine exposure were quantitatively performed using the An-
nexin V-fluorescein isothiocyanate (FITC) Apoptosis Detection Kit (BD Biosci-
ence, San Jose, CA). The cells were cultured at a density of 2 × 105/ml in 24-well 
flat bottom microtitre plates (Jet Biofil, Korea) and treated with DOX (0.9 μM) 
and DER (50–250 μM) alone or in combination as described for the MTT assay. 
The cells were trypsinised 72 h after the treatment and washed twice each with 
ice-cold phosphate-buffered saline (PBS) consisting of 0.01 M phosphate buffer, 
0.0027 M potassium chloride and 0.137 M sodium chloride, and then resus-
pended in 100 μl binding buffer [0.1 M Hepes/NaOH (pH 7.4), 1.4 M NaCl, 
25 mM CaCl2] supplemented with 5 μl of FITC-Annexin V and 5 μl of propidium 
iodide (PI). The cell suspension was gently vortexed and incubated for 15 min at 
room temperature in the dark. Following incubation, 400 μl of binding buffer 
was added to each tube and then analysed within 1 h on a FACScan flow cy-
tometer (BD Biosciences) using the standard optics for detecting FL1 (FITC) and 
FL3 (PI). Data were analysed with the CellQuest WinMDI software (BD Biosci-
ences, San Jose, CA). The apoptotic index (%) was calculated as the sum of early 
and late apoptotic cells. 
Nitric oxide assay  
Since nitric oxide (NO) is very labile, its direct measurement in biological 
samples is difficult. In aqueous solution, NO reacts with molecular oxygen and 
accumulates in the supernatants of cells as nitrite (NO2–) ions. This stable oxida-
tion end product is readily measured in biological samples and has been used in 
vitro and in vivo as an indicator of NO production (Akdeniz et al., 2004). The 
concentration of nitrite in the supernatants of cells was taken as a measure of the 
oxidation product of NO and quantified by a colorimetric assay based on the 
Griess reaction. For this purpose, the cells were cultured at a density of 2 × 
105/ml in 24-well flat bottom microtitre plates and treated with DOX (0.9 μM) 
and DER (50–250 μM) alone or in combination as described for the apoptosis as-
say. At the end of the 72-h incubation period the supernatants were collected. 
Briefly, 100 µL of supernatant from each well was mixed with 100 µL of Griess 
reagent (1% sulphanilamide in 5% phosphoric acid and 0.1% naphthylethyl-
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enediamine dihydrochloride in water) in a separate 96-well plate. After a 5-min 
incubation at room temperature, the optical density was determined at 530 nm 
with a microplate reader and NO2 levels were measured by comparison to the so-
dium nitrite (NaNO2) standard curve (Chen et al., 2008). 
Statistical analysis 
All experiments were run in triplicate and the results were expressed as the 
mean ± SE. The values were initially subjected to one-way ANOVA, which re-
vealed significant differences between groups, followed by Duncan’s test, which 
revealed significant differences between three sample means (SPSS 11.5 statisti-
cal package, Chicago, IL). A difference in the mean with P values of 0.05 or less 
was considered to be statistically significant. 
 
 
Results 
Cell viability assay 
To determine the effects of DOX and DER as single agents on cell viabil-
ity of normal canine mammary epithelial cells, MTT assay was performed. DOX 
at the concentration of 0.9 μM was found to significantly (P < 0.05) inhibit the 
viability (33.63%) of the cells after 72-h incubation. At the same time, DER (50–
250 μM) alone had no significant effect (P > 0.05) on the cell viability of normal 
canine mammary epithelial cells (Fig. 1). These results suggest that DER concen-
trations below ≤ 250 μM were non-toxic to the cells. Thus, the cells were treated 
with DER in concentrations ranging from 50 to 250 μM for all follow-up ex-
periments. Subsequently, we tested 0.9 μM of DOX in combination with 50, 100 
and 250 μM of DER to determine whether DER prevents the cytotoxic effect of 
DOX on canine mammary epithelial cells. As shown in Fig. 1, DER prevented 
the cytotoxic effect of DOX (0.9 μM) on canine mammary epithelial cells. The 
influence of DER on the cytotoxic effect of DOX (0.9 μM) appeared to be mod-
erately dose independent, and the strongest prevention, approaching 86.6% (cell 
viability), was observed with the combination of DOX at 0.9 μM and DER at 
50 μM (P < 0.05). Also, DER at 100 μM concentration decreased the cytotoxic 
activity of DOX (0.9 μM) in canine mammary epithelial cells, which increased 
the proportion of viable cells from 66.37% to 74.18% (P < 0.05). 
Apoptosis assay 
In order to elucidate whether the proliferative/cytotoxic effects of DER 
and DOX alone and in combination on canine mammary epithelial cells were 
mediated via an apoptotic pathway, apoptotic activities were measured by flow 
cytometry. The apoptosis assay was performed using concentrations of DOX 
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(0.9 μM) and DER (50–250 μM) that cannot lead to toxicity. Treatment with 
DOX (0.9 μM) alone induced 36.24% and DER (at 50 μM, 100 μM and 250 μM) 
induced 4.99%, 22.74% and 27.74% early apoptosis and 4.32%, 5.85% and, 
7.13% late apoptosis, respectively, in canine mammary epithelial cells (Fig. 2). 
Combined treatment with DOX and DER (50 μM and 100 μM) significantly (P < 
0.001) decreased the apoptosis index (in terms of the sum of early and late apop-
totic cells; from 36.24% to 10.15% and 11.93%, respectively), as compared with 
that caused by DOX. Quantification and statistical analysis of the results ob-
tained by flow cytometry for each condition is shown in Fig. 3 and Table 1. 
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Fig. 1. Effect of doxorubicin (DOX) and deracoxib (DER) on the viability of normal canine  
mammary epithelial cells. Cells were incubated with DOX and DER and with their combination at 
the indicated concentrations for 72 h. Cell viability was measured by MTT assay. Values are  
expressed as the mean percentage of cell viabilities ± standard error (SE) of three independent  
experiments. DOX (0.9 µM) was compared to the control group. Combination treatments were 
compared to the DOX-treated (0.9 µM) group. *P < 0.05, **P < 0.01, ***P < 0.001 
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Fig. 2. Effects of doxorubicin (DOX) and deracoxib (DER) treatment on apoptosis of normal  
canine mammary epithelial cells. The number of viable, early apoptotic, late apoptotic and necrotic 
cells due to treatment with DOX and DER for 72 h. The experiment was conducted in three  
replicates. Data are expressed as the mean ± standard error (SE). DOX (0.9 µM) was compared to 
the control group. Combination treatments were compared to the DOX-treated (0.9 µM) group  
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Table 1 
Apoptotic index values of canine mammary epithelial cells after 72-h exposure to DOX and DER 
combination 
Concentrations of drugsa (µM) Apoptotic index (%) 
Control 6.36 ± 0.24 
DOX 0.9 36.24 ± 0.25 
DOX 0.9 + DER 50 10.15 ± 0.023*** 
DOX 0.9 + DER 100 11.93 ± 0.24*** 
DOX 0.9 + DER 250 24.55 ± 0.32*** 
aDOX = doxorubicin; DER = deracoxib. Each value repre-
sents the mean ± SE of three experiments. ***P < 0.001 
compared to DOX 
Nitric oxide assay 
In order to study the role of NO production in DOX-induced apoptosis, the 
concentration of nitrite in the supernatants of cells was measured. The level of 
NO2 in cells exposed to DOX (0.9 μM) was increased prominently (P < 0.001); 
in contrast, the levels of NO2 did not differ significantly between the DER-
treated cells in comparison with the control. However, with the combination of 
DOX (0.9 μM) with DER (especially at low concentrations, 50 and 100 μM) the 
levels of NO2 were significantly (P < 0.05) decreased when compared with DOX 
(0.9 μM) alone (Fig. 4). 
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Fig. 4. Effect of doxorubicin (DOX) and deracoxib (DER) treatment on NO2 levels of normal  
canine mammary epithelial cells. Cells were incubated with DOX and DER and with their  
combination at the indicated concentrations for 72 h. NO2 levels were measured by Griess reaction. 
Values are expressed as the mean percentage of cell viabilities ± standard error (SE) of three  
independent experiments. DOX (0.9 µM) was compared to the control group. Combination  
treatments were compared to the DOX-treated (0.9 µM) group 
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Discussion 
Chemotherapeutic agents used in current clinical practice have played a 
significant role in reducing mortality/morbidity and in increasing the quality of 
life of both companion animals and humans (Gustafson and Page, 2013). How-
ever, most anticancer drugs have a narrow therapeutic index, develop multidrug 
resistance and present unacceptable side effects to healthy tissues. These limita-
tions of conventional chemotherapeutic strategies frequently result in suboptimal 
dosing, treatment delay or discontinuance, and reduced patient compliance to 
therapy (Ismael et al., 2008). Therefore, novel therapeutic approaches are needed 
to both improve the outcome of patients suffering from tumours and to minimise 
the long-term toxicities associated with the current standard of treatment. Drug 
development strategies include the evaluation of new drug combinations that 
may have improved efficacy compared with single agents. By treating a tumour 
with a combination of drugs which employ different mechanisms of action and 
have different spectra of normal tissue toxicity, the overall response can be en-
hanced without an increase in toxicity (Narang and Desai, 2009; Al-Lazikani, et 
al., 2012). 
NSAIDs are among the most widely used medications as analgesics and 
antipyretics. Currently, there is a growing interest in their antitumour activity and 
their ability to reduce the risk and mortality of several cancers (Pereg and Lish-
ner, 2005; Wolfesberger et al., 2006; McMillan et al., 2011). A number of both 
clinical and preclinical studies suggest that the combined use of NSAIDs and 
conventional therapies may improve patient prognosis (van Wijngaarden et al., 
2007; Falandry et al., 2009; Rayburn et al., 2009). Although the underlying 
mechanisms of action for the effects NSAIDs as adjuvants are fully demon-
strated, three primary modes of action have been proposed: chemoprotection, al-
terations in pharmacokinetics or metabolism, and chemosensitisation (Rayburn et 
al., 2009). Related studies have shown that especially selective COX-2 inhibitors 
strengthen the effectiveness of chemotherapy treatment in various tumour types 
of dogs, including transitional cell carcinoma and osteosarcoma (Wolfesberger et 
al., 2006; McMillan et al., 2011). Similarly, in our previous study we proved that 
DER used at 50–250 µM concentrations sensitised canine mammary cancer cells 
(CMT-U27) to the cytotoxic action of DOX (0.9 µM, the IC50 for CMT-U27). It 
was elucidated that DER enhanced the antiproliferative effect of DOX in con-
junction with induction of apoptosis by modulation of Bcl-2 expression and 
changes in the cell cycle of the CMT-U27 cell line (Bakirel et al., 2016). Also, 
some studies have explored the therapeutic benefit of COX inhibitors against the 
toxicity of conventional chemotherapeutic agents and have shown that COX-2 
inhibitors are able to attenuate the effect of certain cytotoxic agents such as 
DOX-induced oxidative damage by modulating oxidant status in CMT cells 
(Rayburn et al., 2009; Ustun Alkan et al., 2014). However, the possible role of 
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DER, a highly selective canine COX-2 inhibitor accepted as safe and well toler-
ated in dogs (Roberts et al., 2009), against the toxicity of DOX, a cytotoxic agent 
commonly used in veterinary clinical treatments for various cancers (Pagnini et 
al., 2000), on non-malignant cells is unknown. Our results demonstrated that 
DER at 50 and 100 μM concentrations decreased the cytotoxic action of DOX at 
0.9 μM in cultured normal canine mammary epithelial cells, from 33.63% to 
13.4% and 25.82%, respectively. Therefore, we suggest that DER, at concentra-
tions 50 and 100 μM that do not affect cell viability, can be beneficial through its 
ability to enhance the protection of normal cells from chemotherapeutic toxicity. 
On the other hand, our previous study has demonstrated that under the same ex-
perimental conditions DER sensitised canine mammary cancer cells (CMT-U27) 
to the action of DOX (Bakirel et al., 2016). The discrepancy in cytotoxic activity 
may depend on the preferential uptake of these drugs in cancer cells to normal 
cells. Cancerous cells possess structural features such as membrane structure, 
protein composition and bigger size that are different from those of normal pro-
liferating cells, so it is possible that drug concentrations in the tumour cells are 
higher than in normal cells (Kunwar et al., 2008; Leth-Larsen et al., 2010). Also, 
different effects of NSAIDs on normal and cancer cells are attributed to the dis-
tinctive nature of these drugs for selectively targeting cancer cells (Ralph et al., 
2015). To date, NSAIDs in combination with chemotherapy have been shown to 
have differential effects on normal cells such as normal mouse embryo cell line 
and normal primary B cells in comparison with cancer cells (Jastrzebska et al., 
2013; Gallouet et al., 2014). However, the molecular and cellular mechanisms 
underlying the alterations in outcome that occur in response to this combination 
therapy have not been fully understood. In this study, our results have shown that 
the reverse effect of DER (especially at 50 and 100 μM concentrations) on the 
anti-proliferative activity induced by DOX alone on normal canine mammary 
epithelial cells is associated with a marked (3.04–3.57-fold) decrease in apop-
tosis. We suggest that DER may protect the cells against DOX by inhibiting the 
apoptotic programme. Also, our results have demonstrated that DOX alone 
caused late apoptosis rather than early apoptosis. The number of late apoptotic 
cells was significantly decreased by the addition of DER in a dose-independent 
manner. An increase in early apoptotic activity indicates that the cells are in a 
static, non-proliferative state, while an increase in late apoptotic activity suggests 
that the cells are in the final stages of the apoptotic cycle and that cell death is 
imminent (Ustun Alkan et al., 2012). Although chemotherapeutic agents may in-
duce apoptosis through the death receptor pathway, the mitochondrial pathway is 
indicated as the primary pathway in anticancer drug-mediated cell killing (Indran 
et al., 2011). This pathway, activated by receptor-independent stimulants such as 
chemotherapeutic agents, proceeds through changes of mitochondrial membrane 
permeability, leading to the release of pro-apoptotic proteins and the arrest of the 
bioenergetic function of the organelle (Shi, 2001; Elmore, 2007). It has been re-
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ported that the release of pro-apoptotic proteins is a late event in apoptosis, which 
occurs once the cells are committed to die (Indran et al., 2011). DOX, which is 
known to trigger apoptotic cell death, induces apoptosis in normal and tumour 
cells via distinctly different mechanisms (Meng et al., 2014). In this context, mi-
tochondrial dysfunction and severe inhibition/inactivation of certain mitochon-
drial system have been implicated as important pathways of apoptosis induced by 
DOX associated with its remarkable toxicity in normal cells (Mizutani et al., 
2005; Octavia et al., 2012). Some studies have suggested that increased oxida-
tive/nitrosative stress associated with an impaired antioxidant defence status 
plays a critical role in DOX-induced mitochondrial dysfunction (Octavia et al., 
2012; Hao et al., 2015). DOX increases mitochondrial superoxide and, conse-
quently, the generation of reactive oxygen species (e.g. H2O2) in endothelial 
cells, leading to enhanced NO generation (Mukhopadhyay et al., 2009). Elevated 
production of NO may cause cell death related to the formation of peroxynitrite, 
which is involved in the inflammatory process (Rehman et al., 2014). Large 
amounts of NO inhibit DNA synthesis, damage DNA and, hence, induce apop-
tosis (Ozen et al., 2001). In an experimental model studying the association of 
NO and apoptosis, Mukhopadhyay et al. (2009) suggested that NO is a major 
trigger/mediator of DOX-induced apoptotic cell death. In the present study, we 
found that DOX induced a marked increase of NO generation, by measuring the 
accumulation of its stable degradation product nitrite in the cells. This result pro-
vides additional support for the above-mentioned theory. On the other hand, the 
DER dose independently attenuated the DOX-induced excess NO production as 
measured by NO2– level (as well as apoptotic activity) in the cells. We suggest 
that DER may have a modulatory role in regulating NO production of the cells 
against DOX. Our observation is consistent with the findings of Ozgocmen et al. 
(2005), who demonstrated that NSAIDs (e.g. celecoxib and tenoxicam) may re-
duce nitrite levels, indicating an alteration in the NO pathway. Similarly, Asa-
numa et al. (2001) reported that the protective effect of some NSAIDs (aspirin, 
mefenamic acid, indomethacin and ketoprofen) against NOC18-induced apop-
tosis might be mainly due to their direct NO radical scavenging activities in neu-
ronal cells (Asanuma et al., 2001). Although the mechanisms of the inhibitory ef-
fects of NSAIDs against inflammatory mediator and cytotoxic agent induced in-
creases in NO production in cells have not been completely defined (Asanuma et 
al., 2001; Abou El Hassan et al., 2003) some studies have reported that NSAIDs 
have a blocking effect on NO production through their inhibiting effects on 
iNOS (Farivar et al., 1996; Du and Li, 1999; Sanchez de Miguel et al., 1999). In 
this respect, we suggest that DOX-induced NO production in cultured epithelial 
cells might be caused by the reactive oxygen species-induced promotion of NF-
κB (Schreck et al., 1991; Meyer et al., 1993) and the protective effect of DER 
against DOX-induced apoptotic nuclear changes might be due mainly to its direct 
scavenging activity on produced intracellular NO in the epithelial cells. 
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In summary, our in vitro study results indicate that DER, especially at low 
concentrations (50 and 100 μM) not affecting cell viability, can be beneficial in 
protecting normal cells from the toxic effect of DOX in conjunction with apop-
tosis by the modulation of NO production. We have concluded that the addition 
of DER (50–100 μM) to DOX (0.9 μM) therapy may be beneficial in minimising 
the damage to normal tissues. 
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